Andrew Tutt, PhD, MBChB, on Breast Cancer: Olaparib After Chemotherapy in Germline BRCA1/2–Mutated Tumors

June 04, 2021 By The ASCO Post Staff

Andrew Tutt, PhD, MBChB, of the Institute of Cancer Research, London, discusses findings from the phase III OlympiA trial, which showed that adjuvant olaparib, a PARP inhibitor, following adjuvant or neoadjuvant chemotherapy, may improve invasive disease–free survival in patients with germline BRCA-mutated and high-risk HER2-negative early breast cancer, which might lead to a new indication in this setting (Abstract LBA1).

Related Content